This story has been updated to reflect NeoGenomics' estimate on the valuation of the common stock portion of the deal and include debt the firm has taken on to finance it.
NEW YORK (GenomeWeb) – NeoGenomics today announced it has signed a definitive agreement to acquire cancer molecular diagnostics firm Clarient in a cash and stock deal worth approximately $275 million.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.
An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.
The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.
For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.